Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) Sort descending | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
1R34DA050272-01
Show Summary |
1/2 Optimizing access, engagement and assessment to elucidate prenatal influences on neurodevelopment: The Brains Begin Before Birth (B4) Midwest Consortium | Enhanced Outcomes for Infants and Children Exposed to Opioids | HEALthy Brain and Child Development Study (HBCD) | NIDA | WASHINGTON UNIVERSITY | ROGERS, CYNTHIA ELISE (contact); SMYSER, CHRISTOPHER DANIEL | St. Louis, MO | 2019 |
NOFO Title: HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) (Collaborative R34 Clinical Trial Not Allowed)
NOFO Number: RFA-DA-19-029 Summary: Though prenatal exposure to opioids and other substances have adverse effects on neurodevelopment, advances in neuroimaging and developmentally sensitive phenotypic measurement now enable characterization of typical and atypical brain-behavior pathways on an unprecedented scale. The Brains Begin Before Birth (B4) Midwest Consortium, a partnership of neuroscience, substance use, perinatal mental health, and child welfare scientists at Washington University School of Medicine (WUSM) and neuroscience, bioethics, pediatric population health, maternal-fetal, and addiction scientists at Northwestern University (NU). This regional consortium will leverage the contrasting approaches of Illinois (punitive) and Missouri (non-punitive) to prenatal opioid use, providing a platform for examining the impact of jurisdictional variations on science and practice. The consortium provide a framework for addressing three major areas of challenge: (1) legal/ethical, (2) recruitment/retention, and (3) imaging/assessment methods. |
||||||||
1UG3DA050303-01
Show Summary |
Development of an implantable closed-loop system for delivery of naloxone for the prevention of opioid-related overdose deaths | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | Washington University | Rogers, John | St. Louis, MO | 2019 |
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
NOFO Number: RFA-DA-19-002 Summary: Current opioid overdose treatment requires administration of naloxone by first responders, which requires timely identification of the overdose, the need for a rescue injection, and immediate availability of the medication. The development of a fail-safe treatment that would provide a life-saving dose of naloxone without the need for intervention by another party could significantly reduce mortality. The researchers aim to develop a new medical device comprising an implantable, closed-loop system that senses the presence of an opioid overdose, automatically administers a life-saving bolus injection of naloxone, and simultaneously alerts first responders. |
||||||||
3U01DA055367-03S1
Show Summary |
23/24 HEALthy Brain and Child Development National Consortium | Enhanced Outcomes for Infants and Children Exposed to Opioids | HEALthy Brain and Child Development Study (HBCD) | NIDA | WASHINGTON UNIVERSITY | ROGERS, CYNTHIA ELISE (contact); BOGDAN, RYAN H | Saint Louis, MO | 2023 |
NOFO Title: Notice of Special Interest (NOSI): HEAL Initiative: Biospecimen Collection in Pregnancy
NOFO Number: NOT-DA-23-005 Summary: Opioid use during pregnancy is associated with adverse outcomes for pregnant individuals and offspring. The mechanisms through which these outcomes arise and the consequences of prenatal opioid exposure on child health and development remain largely unexplored. The HEALthy Brain and Child Development (HBCD) Study is a nationwide longitudinal prospective study of early child development that will assess a broad spectrum of biological, behavioral, social, and health factors among 7,500 pregnant women and their children from pregnancy to mid-childhood. This supplement will expand the biospecimen collection of the HBCD protocol at the University of North Carolina at Chapel Hill to include delivery specimens (placenta, cord tissue, and cord blood). This will provide an unprecedented resource-generating opportunity for the larger scientific community to comprehensively evaluate mechanisms that mediate the connection between substance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and inform innovative preventive strategies. |
||||||||
1U24DA055330-01
Show Summary |
Healthy Brain and Child Development National Consortium Data Coordinating Center | Enhanced Outcomes for Infants and Children Exposed to Opioids | HEALthy Brain and Child Development Study (HBCD) | NIDA | WASHINGTON UNIVERSITY | SMYSER, CHRISTOPHER DANIEL (contact); DALE, ANDERS M; FAIR, DAMIEN A | St Louis, MO | 2021 |
NOFO Title: HEAL Initiative: HEALthy Brain and Child Development Data Coordinating Center (U24)
NOFO Number: RFA-DA-21-023 Summary: The HEALthy Brain and Child Development National Consortium (HBCD-NC) Data Coordinating Center (HDCC) will provide data management and oversight to all HBCD-NC sites to ensure the consortium’s primary objective of establishing a normative template of developmental trajectories over the first 10 years of life is met. The HBCD-NC will collect neural, behavioral, physiological, and psychological measures, as well as biospecimens, to characterize neurodevelopmental trajectories. The HDCC will coordinate data collection, data quality, data harmonization, data sharing, and data analysis efforts that are central to the consortium’s ability to implement a common research protocol. The HDCC will assemble all data across the consortium sites and distribute a comprehensive and well curated research dataset to the scientific community at large. The HDCC is tightly integrated with the HEALthy Brain and Child Development Administrative Core (HCAC) and includes a multi-institution investigative team at the University of Minnesota, University of California, San Diego, and Washington University at St Louis. |
||||||||
1K01DA058750-01
Show Summary |
Leveraging mHealth to Increase Health Equity Among Black Individuals with OUD and Commonly Occurring Mental Health Disorders | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIDA | WASHINGTON UNIVERSITY | SZLYK, HANNAH | Saint Louis, MO | 2023 |
NOFO Title: HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)
NOFO Number: PAS-22-206 Summary: This project provides protected time for training and research activities that are required for an independent scientific career in the development, testing, and implementation of cutting-edge digital therapies and tools (such as smartphone apps and other web-based resources) that can promote health equity in treatment of opioid use disorder (OUD). The research will adapt and test digital overdose prevention and recovery support interventions for Black Americans with co-occurring OUD and mental illness. |
||||||||
3U24DA055330-03S1
Show Summary |
HEALthy Brain and Child Development National Consortium Data Coordinating Center | Enhanced Outcomes for Infants and Children Exposed to Opioids | HEALthy Brain and Child Development Study (HBCD) | NIDA | WASHINGTON UNIVERSITY | SMYSER, CHRISTOPHER DANIEL (contact); FAIR, DAMIEN A | Saint Louis, MO | 2023 |
NOFO Title: Notice of Special Interest (NOSI): HEAL Initiative: Biospecimen Collection in Pregnancy
NOFO Number: NOT-DA-23-005 Summary: Opioid use during pregnancy is associated with adverse outcomes for pregnant individuals and offspring. The mechanisms through which these outcomes arise and the consequences of prenatal opioid exposure on child health and development remain largely unexplored. The HEALthy Brain and Child Development (HBCD) Study is a nationwide longitudinal prospective study of early child development that will assess a broad spectrum of biological, behavioral, social, and health factors among 7,500 pregnant women and their children from pregnancy to mid-childhood. This supplement will expand the biospecimen collection of the HBCD protocol at the University of North Carolina at Chapel Hill to include delivery specimens (placenta, cord tissue, and cord blood). This will provide an unprecedented resource-generating opportunity for the larger scientific community to comprehensively evaluate mechanisms that mediate the connection between substance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and inform innovative preventive strategies. |
||||||||
1R61AT012283-01
Show Summary |
Development and Identification of Magnetic Resonance, Electrophysiological, and Fiber-Optic Imaging Biomarkers of Myofascial Pain | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NCCIH | WASHINGTON UNIVERSITY | HU, SONG (contact); WANG, YONG | St. Louis, MO | 2022 |
NOFO Title: HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management
NOFO Number: RFA-AT-22-003 Summary: Pain in muscles and surrounding connective tissue (myofascial pain) is a significant health concern affecting hundreds of millions of Americans. There is no objective way to identify and measure myofascial pain. This project will address this unmet challenge by developing a robust approach to identify imaging biomarker(s) that can distinguish different states of myofascial pain. The research will then examine the ability of identified biomarker(s) to predict patient responses to a myofascial pain treatment in a randomized controlled clinical trial. |
||||||||
1R01HD113199-01
Show Summary |
The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta Project (OPIOID BPP) | Enhanced Outcomes for Infants and Children Exposed to Opioids | The Biology of Opioid Exposure During Pregnancy and Effects on Early Neuro-Behavioral Development | NICHD | WASHINGTON UNIVERSITY | KELLY, JEANNIE CHEN (contact); WANG, YONG | Saint Louis, MO | 2023 |
NOFO Title: HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-HD-23-030 Summary: Opioid use disorder during pregnancy is associated with poor infant outcomes including neonatal opioid withdrawal syndrome (NOWS) and impaired brain development during childhood. This project will use advanced imaging techniques to measure inflammation in the placenta and evaluate brain structure of the developing fetus. These data will be combined with measures of infant NOWS and neurodevelopmental outcomes at birth and 1 year of age. This research will explore the value of these imaging methods as diagnostic tools for infants exposed to opioids during pregnancy. The research will also study the effect of opioids on the placenta’s ability to provide oxygen to the growing fetus as well as the potential for inflammation to damage the placenta and harm development of the fetal brain. |
||||||||
1R44DA058431-01
Show Summary |
Development of an AI-Empowered Device that Utilizes Multimodal Data-Visualization to Aid in the Diagnosis, and Treatment, of OUD | Cross-Cutting Research | Small Business Programs | NIDA | WAVI COMPANY | ARESE LUCINI, FRANCESCA | Englewood, CO | 2023 |
NOFO Title: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-021 Summary: There are a lack of clinical tools to effectively identify and monitor opioid use disorder (OUD). This project will develop and test a clinically usable device that uses a range of data inputs and an artificial intelligence (AI) algorithm to help health care providers diagnose and treat OUD. The research aims to help providers choose treatment plans and monitor the timing of release from rehabilitation clinics. |
||||||||
1U01HL150551-01
Show Summary |
Dual-orexin antagonism as a mechanism for improving sleep and drug abstinence in opioid use disorder | New Strategies to Prevent and Treat Opioid Addiction | Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery | NHLBI | Wayne State University | GREENWALD, MARK K (contact); ROEHRS, TIMOTHY A | Detroit, MI | 2019 |
NOFO Title: HEAL Initiative: Sleep and Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to Medication Assisted Treatment (MAT) (U01 Clinical Trial Optional)
NOFO Number: RFA-HL-19-029 Summary: FDA-approved medications for treating opioid use disorder are effective, but there is a significant unmet need for alternatives, especially relapse prevention. NIDA and the FDA have encouraged investigators to expand the range of therapeutic outcomes, beyond measurement of abstinence. Insomnia is a clinically significant, but understudied, correlate/predictor of relapse to substance use. Yet most medications for treating insomnia have limited efficacy and can produce side effects. The orexin (OX) system plays a key role in sleep and substance use, offering a promising avenue for study. This project will address whether OX-1/2 antagonism is a mechanism that can directly improve outpatient opioid abstinence, or whether OX antagonism corrects sleep deficiencies and indirectly improves opioid abstinence. Specific aims are to determine whether nightly treatment with the OX-1/2 antagonist suvorexant, relative to placebo, 1) increases outpatient opioid abstinence and 2) improves sleep efficiency on the residential detoxification unit. The study will also determine 3) whether improved sleep efficiency predicts greater opioid abstinence (regardless of group assignment). |
||||||||
1R21DA047662-01
Show Summary |
Human laboratory model to screen drugs with opioid analgesic-sparing effects: cannabidiol/morphine combinations | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | WAYNE STATE UNIVERSITY | Lundahl, Leslie H | Detroit, MI | 2019 |
NOFO Title: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
NOFO Number: PA-18-344 Summary: Chronic pain is a significant public health problem associated with tremendous personal and economic burden. First-line treatment consists of opioid medications, but despite only moderate efficacy and unpleasant side effects, rates of opioid prescriptions have quadrupled over the past 15 years, and this has contributed to high rates of misuse, overdose, and mortality. Clearly, alternative, or non-opioid strategies for treating pain are needed. In this context, “opioid-sparing” medications refer to compounds that can be combined with and enhance the analgesic effects of lower-dose opioids without increasing the rewarding properties of either drug. There is preclinical evidence suggesting that cannabidiol (CBD) may have the potential to function as “opioid-sparing” medications, but its ability to alter opioid-mediated analgesia in humans has yet to be determined. This proposal will fill this gap by conducting a double-blind, placebo-controlled, within-subject randomized crossover study of the effects of CBD and morphine co-administration on pain sensitivity and subjective reinforcement on 28 healthy males and females. This is the first known study to investigate the ability of CBD to alter morphine’s analgesic effects in humans. If successful, the model will have a lasting impact on our ability to develop and test medications that reduce our reliance on chronic use of opioid medications for pain relief. |
||||||||
1R01DA057654-01
Show Summary |
Expansion of Mail-Delivered Harm Reduction Services in the U.S. | Translation of Research to Practice for the Treatment of Opioid Addiction | Harm Reduction Approaches to Reduce Overdose Deaths | NIDA | WEILL MEDICAL COLL OF CORNELL UNIV | BEHRENDS, CZARINA NAVOS | New York, NY | 2022 |
NOFO Title: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-22-046 Summary: Harm reduction supplies include fentanyl test strips that allow people who use drugs to identify whether the substance(s) they plan to take contain fentanyl and sterile syringes that help to prevent the spread of infectious diseases among people who inject drugs. One potential way to increase access to harm reduction supplies is mail delivery. This project will describe state-level policies that deter the use of mail-based delivery of harm reduction services, examine characteristics of people who use mail-based harm reduction services, and assess individual preferences related to mail-based harm reduction services. |
||||||||
1U24DA057650-01
Show Summary |
HEAL Data2Action Modeling and Economic Resource Center | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | WEILL MEDICAL COLL OF CORNELL UNIV | SCHACKMAN, BRUCE R (contact); LINAS, BENJAMIN P; MCCOLLISTER, KATHRYN E | New York, NY | 2022 |
NOFO Title: HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional)
NOFO Number: RFA-DA-22-049 Summary: This project creates the HEAL Data2Action Modeling and Economic Resource Center that will conduct research as well as support the HEAL Data2Action Innovation Projects with expertise and consultation about simulation modeling and economic evaluation methods. The consultation service will advise on how to select and use various research methods, including economic evaluation, simulation modeling, advanced statistical analysis, behavioral economics, treatment program organization research, and cost analysis. The center will use a dynamic simulation model of opioid use disorder to enhance data-driven decision making. The center will also provide online training resources, tools, and other resources to assess a variety of economic aspects related to the HEAL Data2Action Innovation Projects. |
||||||||
1UG3NS114947-01
Show Summary |
Novel HCN1-selective small molecule inhibitors for the treatment of neuropathic pain | Preclinical and Translational Research in Pain Management | Development and Optimization of Non-Addictive Therapies to Treat Pain | NINDS | WEILL MEDICAL COLL OF CORNELL UNIV | GOLDSTEIN, PETER A | New York, NY | 2019 |
NOFO Title: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-19-010 Summary: Neuropathic pain is characterized by neuronal hyperexcitability and spontaneous activity, properties associated with activity of hyperpolarization-activated, cyclic nucleotide-regulated (HCN1-4) channels, the source of the pacemaker current, Ih. Inhibition of HCN1-mediated Ih elicits marked antihyperalgesia in multiple animal models of neuropathic pain, including models for direct nerve injury and chemotherapy-induced peripheral neuropathy, and does so with little or no disruption to either normal pain processing or baseline behaviors and activities. The overall objective is to develop a peripherally restricted HCN1 inverse-agonist as a therapeutic for neuropathic pain. Researchers have generated a novel small molecule that combines an antihyperalgesic HCN1 inhibitor with a motif that controls distribution and membrane presentation and is a potential non-opioid antihyperalgesic treatment for peripheral neuropathic pain. |
||||||||
5UG3DA047714-02
Show Summary |
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | WEST VIRGINIA UNIVERSITY | Rezai, Ali R | Morgantown, WV | 2019 |
NOFO Title: Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
NOFO Number: PAR-18-494 |
||||||||
1R21DA049861-01
Show Summary |
Impact of SB 273 on West Virginia Patients, Providers and Overall Prescription Rates of Opioid Medications | New Strategies to Prevent and Treat Opioid Addiction | Preventing Opioid Use Disorder | NIDA | West Virginia University | Cara Sedney; Treah Haggerty | Morgantown, WV | 2019 |
NOFO Title: Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
NOFO Number: PAR-19-064 Summary: In 2018, new opiate prescribing limits (SB 273) were implemented across West Virginia to combat the opiate misuse epidemic. This study will utilize quantitative and qualitative measures to determine the effect of the recent opiate prescription laws in West Virginia, how a change in policy affects the opiate misuse epidemic, and how communities may apply this knowledge more broadly. The research team will: 1) collaborate with the West Virginia Board of Pharmacy to ascertain changes in opiate prescribing habits before and after the start of SB 273 using an interrupted time series methodology, and 2) achieve broad and deep understanding of how SB 273 has affected prescribing practices and experiences amongst primary care physicians, specialists (pan physicians, surgeons, emergency room physicians, etc.), and patients who currently or previously utilized opiate medications. |
||||||||
3U54GM104942-03S1
Show Summary |
WEST VIRGINIA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: IMPROVING HEALTH THROUGH PARTNERSHIPS AND TRANSFORMATIVE RESEARCH | New Strategies to Prevent and Treat Opioid Addiction | NIGMS | West Virginia University | HODDER, SALLY LYNN | MORGANTOWN, WV | 2018 | |
NOFO Title: Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54)
NOFO Number: PAR-14-303 Summary: Mortality rates in Appalachia have progressively increased over recent years, in contrast to decreasing mortality rates observed in the remainder of the U.S. The West Virginia Clinical and Translational Science Institute (WVCTSI) was created in 2012 through the initial Clinical and Translational Research (CTR) award and has subsequently formed a well-connected, statewide research network, creating the infrastructure to address the substantial health disparities that exist in West Virginia. WVCTSI is now well positioned to attain the goals of this renewal application that include: 1) building sustainable research infrastructure that substantively contributes to improving West Virginia health outcomes by 2022; 2) recruiting the next generation of clinician scientists and translational researchers that excel in team science and are positioned for long-term success; and 3) actively engaging with multiple stakeholders that include communities, medical providers, and policy makers to drive research that improves the health of West Virginians. |
||||||||
3UH3DA047714-04S1
Show Summary |
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | WEST VIRGINIA UNIVERSITY | REZAI, ALI R | Morgantown, WV | 2023 |
NOFO Title: Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
NOFO Number: PA-20-272 Summary: Novel treatments for opioid use disorder are critically needed as the addiction and overdose crises continue. Neuromodulation is a promising supplemental treatment to standard care. The overarching project seeks to evaluate low-intensity focused ultrasound that targets the nucleus accumbens, a primary component of the brain’s reward neurocircuitry. This supplement will expand the number of participants in part of the study and will increase the project’s overall impact consistent with the original objectives and aims of the parent grant. |
||||||||
1R34DA050284-01
Show Summary |
1/5 The Cumulative Risk of Substance Exposure and Early Life Adversity on Child Health Development and Outcomes | Enhanced Outcomes for Infants and Children Exposed to Opioids | HEALthy Brain and Child Development Study (HBCD) | NIDA | WOMEN AND INFANTS HOSPITAL-RHODE ISLAND | DEONI, SEAN CL (contact); AMSO, DIMA ; D'SA, VIREN ANDREW; MUELLER, HANS-GEORG | Providence, RI | 2019 |
NOFO Title: HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) (Collaborative R34 Clinical Trial Not Allowed)
NOFO Number: RFA-DA-19-029 Summary: Despite increased efforts to understand the neurodevelopmental sequelae of in utero opioid and other substance exposure on long-term behavioral, cognitive, and societal outcomes, important questions remain, specifically, 1) How is brain growth disrupted by fetal substance and related pre- and post-natal exposures? and 2) How are these disrupted growth patterns causally related to later cognitive and behavioral outcomes? This project seeks to formulate an approach to addressing these key questions and decipher the individual and cumulative effect of these intertwined pre- and post-natal exposures on child neurodevelopment. First, researchers will address the legal, ethical, and mother-child care and support concerns implicit in this study. Next, they will integrate across our areas of neuroimaging expertise to develop, implement, and harmonize a multi-modal MRI and EEG protocol to assess maturing brain structure, function, and connectivity. Finally, researchers will develop and test advanced statistical approaches to model and analyze this multidimensional and longitudinal data. |
||||||||
1UG3NS135168-01
Show Summary |
IMPACT: Integrative Mindfulness-Based Predictive Approach for Chronic low back pain Treatment | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NINDS | WORCESTER POLYTECHNIC INSTITUTE | KING, JEAN A (contact); AGU, EMMANUEL; MORONE, NATALIA E | Worcester, MA | 2023 |
NOFO Title: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-22-050 Summary: Chronic low back pain affects millions of people in the United States, resulting in high medical costs and lost productivity. New opioid-free treatments are needed to help people with chronic low back pain, but not all people respond equally to a given approach. IMPACT aims to use machine learning to analyze data such as physical activity, sleep, emotions, and pain levels and identify markers that can help predict how effective a mindfulness-based treatment approach (Mindfulness-Based Stress Reduction) can be for people with chronic low back pain. |
||||||||
1U24DA058673-01
Show Summary |
Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long-Term Opioid Therapy - Yale Resource Center (MIRHIQL-YRC) | Clinical Research in Pain Management | Reducing Opioid-Related Harms to Treat Chronic Pain (IMPOWR and MIRHIQL) | NIDA | YALE UNIVERSITY | BECKER, WILLIAM C (contact); BLACK, ANNE C; DEBAR LYNN L; EDMOND, SARA; ESSERMAN, DENISE | New Haven, CT | 2023 |
NOFO Title: HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL): Resource Center (U24- Clinical Trial Optional)
NOFO Number: RFA-DA-23-042 Summary: Decreasing opioid dosing faster than advised by clinical recommendations often leaves chronic pain unaddressed and may increase the risk of overdose and suicide compared to continuing long-term opioid treatment. The MIRHIQL Resource Center will provide infrastructure support for the network as well as create a risk-benefit decision tool to help providers determine when opioids should be continued as prescribed, tapered, or tapered/discontinued. The center will first develop and validate a clinical definition for individuals who take long-term opioids, then study long-term outcomes in participants who receive treatment in primary care settings. This research will partner with many groups including individuals with lived experience, community health care providers who treat such individuals, research scientists, bioethicists, and professional societies |
||||||||
3UH3DA050251-03S1
Show Summary |
The Role of Family Functioning and Race/Ethnicity on the Efficacy of an Opioid Misuse Prevention Videogame Intervention for Adolescents | New Strategies to Prevent and Treat Opioid Addiction | Preventing Opioid Use Disorder | NIDA | YALE UNIVERSITY | FIELLIN, LYNN ELIZABETH | New Haven, CT | 2021 |
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
NOFO Number: NOT-NS-20-107 Summary: Most opioid misuse begins during adolescence and young adulthood. Adolescence is the best time for prevention interventions in settings like school-based health centers (HCs), yet few programs focus on preventing initiation of opioid misuse. This study harnesses the power of video game interventions and incorporates components of effective substance use prevention programs to develop an evidence-informed intervention to prevent the initiation of opioid misuse in adolescents. In partnership with the national School-Based Health Alliance (SBHA), researchers will develop and test a new video game intervention, PlaySmart. It will build on our previous video game intervention that has demonstrated efficacy in improving attitudes and knowledge related to risk behaviors. The study will evaluate the game in a randomized controlled trial in 10 school-based HCs and examine strategies for implementing PlaySmart in school-based HCs nationally. This research has considerable potential for wide implementation, reach, and impact on high-risk adolescents through school-based HCs. |
||||||||
1R01DA047094-01A1
Show Summary |
Guanfacine Target Engagement and Validation to Improve Substance Use Outcomes in Women | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | YALE UNIVERSITY | Sinha, Rajita | New Haven, CT | 2019 |
NOFO Title: NIH Research Project Grant (Parent R01 Clinical Trial Required)
NOFO Number: PA-18-345 Summary: There are currently no FDA-approved treatments for cocaine use disorder (CUD) or co-occurring substance use disorder. High relapse rates pose a major obstacle to treatment, and this is due in part to the way that high drug cravings reduce individuals’ cognitive flexibility in situations where they are stressed or exposed to drug-related cues. These effects appear to be stronger in women with CUD than in men. Building on preliminary data that a drug called Guanfacine reverses these effects in women, but not in men, this 3-year pilot clinical study will test whether Guanfacine will reduce cocaine use and increase abstinence and will use laboratory challenges to determine whether it reduces cravings and enhances cognitive flexibility in stressful or drug-cue-related situations. |
||||||||
1R01DA057672-01
Show Summary |
A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness | Translation of Research to Practice for the Treatment of Opioid Addiction | Improving Delivery of Healthcare Services for Polysubstance Use | NIDA | YALE UNIVERSITY | MCNEIL, RYAN (contact); KNIGHT, KELLY RAY | New Haven, CT | 2022 |
NOFO Title: HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional)
NOFO Number: DA22-047 Summary: Compared to people with stable housing, individuals experiencing homelessness are more likely to use both fentanyl and stimulants and experience drug-related harms. This project will examine fentanyl-stimulant polysubstance use patterns and how they evolve over time in response to changes to housing status. It will also assess use of overdose prevention and substance use disorder treatment interventions in homeless individuals who use both fentanyl and stimulants, including how polysubstance use patterns shape their risk of overdose over time. This research will also interact with community stakeholders toward translating the findings into future research, policy, and program recommendations. |
||||||||
1R33DA059884-01
Show Summary |
ADAPT: Adaptive Decision Support for Addiction Treatment | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | YALE UNIVERSITY | MELNICK, EDWARD ROBERT | New Haven, CT | 2023 |
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-054 Summary: Computerized clinical decision support tools offer a promising strategy to standardize and scale evidence-based practices to keep pace with the dynamic nature of the opioid crisis and overcome barriers to substance use disorder treatment. To change practice, such tools must be useful, usable, able to be integrated into routine care delivery, and supported by a multicomponent implementation strategy. This project will refine and evaluate the uptake, usability, and equity of a nationally disseminated multicomponent clinical decision support intervention to increase initiation of medication treatment for opioid use disorder in the emergency department. |